Quest Diagnostics Inc.

Quest Diagnostics Inc. is the largest clinical laboratory testing company in the United States, providing diagnostic information services to approximately one-third of the American adult population annually and roughly half over any three-year period, generating $11.0 billion in revenue in fiscal 2025. The company operates a national network of roughly two dozen major laboratories, approximately 2,400 patient service centers, and a logistics fleet that moves specimens from draw sites to testing facilities across the country. Quest sits at the center of the healthcare ecosystem, connecting physicians, hospitals, consumers, health plans, and pharmaceutical companies through the data its tests produce.

This is a story about a business built on relentless operational discipline and scale that is making a deliberate turn toward innovation-led growth. For most of its history, Quest competed on breadth of test menu, geographic reach, and cost efficiency — the advantages of being the biggest player in a fragmented market where the next-largest competitor plus Quest together still represent less than 30% of total industry volume. What has changed in the last three to five years is the emergence of growth vectors that do not depend on taking share from hospital outreach labs: consumer-initiated testing, blood-based diagnostics for Alzheimer's disease and cancer monitoring, and collaborative lab management partnerships with major health systems. The file turns on a single question: whether these new vectors can compound fast enough to shift the growth algorithm from "consolidate, optimize, return capital" to something the market would pay a higher multiple for.

The 2024 acquisition wave — LifeLabs in Canada, five hospital outreach deals, PathAI Diagnostics, and Lenco — added roughly $1.2 billion in annualized revenue and pushed total 2025 revenue past $11 billion for the first time outside a COVID year. The 2026 guidance, raised after a strong first quarter, calls for $11.78-11.9 billion in revenue and adjusted EPS of $10.63-10.83, implying roughly 7-8% top-line growth almost entirely organic. The market is pricing Quest at roughly 21 times trailing earnings and approximately 12.8 times trailing EBITDA — a premium to its own five-year history but a discount to the compounders the management team is trying to emulate.